The drug, known for now as REGN727, lowered bad cholesterol by up to 65 per cent.
It appears to work for patients who can't take statins, the primary drugs used now. And during the study, there were no side effects serious enough to stop the research.
REGN727 is being developed by Sanofi and Regeneron.
It is part of an experimental new class of cholesterol-busting medication called PCSK9 inhibitors.
